Risk stratification for prostate cancer management: value of the Cambridge prognostic group classification for assessing treatment allocation
BMC Medicine Jun 01, 2020
Parry MG, Cowling TE, Sujenthiran A, et al. - This study was attempted to assess radical treatment rates according to Cambridge Prognostic Group (CPG) in men diagnosed with non-metastatic prostate cancer in England between 2014 and 2017. Researchers distinguished patients diagnosed with non-metastatic prostate cancer from the National Prostate Cancer Audit database. They calculated risk ratios (RR) for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically. They applied funnel plots to show variation in radical treatment rates across hospitals. The study population consisted of 61,999 men with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). Men were classified in five risk groups by CPG classification that are about equal in size. it shows variations in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk disease (CPG4 and CPGP5) that are not visible when applying the traditional three-tiered risk classification.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins